Hepatic Encephalopathy Clinical Trial
Official title:
A Study on Early Diagnosis and Treatments of Minimal Hepatic Encephalopathy(MHE) in Patients With Liver Diseases
NCT number | NCT04058327 |
Other study ID # | MHE study |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2019 |
Est. completion date | December 30, 2022 |
Verified date | June 2024 |
Source | Tongji Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study analyzes the diagnostic efficacy of neurophysiological tests and blood biomarkers on MHE, predicts risk factors on the development of OHE and investigate the mortality of MHE in patients with cirrhosis and acute on chronic liver failure.
Status | Completed |
Enrollment | 252 |
Est. completion date | December 30, 2022 |
Est. primary completion date | December 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - >18 years old - cirrhosis - acute on chronic liver failure Exclusion Criteria: (1) status of OHE; (2) accompanying nervous system diseases, such as dementia or stroke; (3) a history of recent head trauma or surgery, and (4) organic lesions in the brain, such as haemorrhages or infarction; (5) inability to finish the psychometric hepatic encephalopathy score (PHES), such as unable to observe patterns or words clearly on paper, and (6) a recent transjugular intrahepatic portosystemic shunt (TIPS) or abdominal imaging demonstrated portosystemic shunts, and (7) high alcohol consumption (> 30 g/day in men or 20 g/day in women) or psychoactive medication consumption in the past four weeks. |
Country | Name | City | State |
---|---|---|---|
China | Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Qin Ning |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression of 2-4 HE | Incidence of HE progression (2/3/4 HE) | 30 days | |
Primary | mortality in short, median and long term | mortality in 30 days, 90 days, 1 year, 2 years, 3 years | 30 and 90 days, 1, 2, 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01846806 -
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
|
N/A | |
Completed |
NCT01559519 -
Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy
|
Phase 4 | |
Recruiting |
NCT01178372 -
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis
|
Phase 4 | |
Completed |
NCT00740142 -
Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy
|
Phase 4 | |
Completed |
NCT00914056 -
A Study of Controlled Lactulose Withdrawal
|
N/A | |
Completed |
NCT00558038 -
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
|
Phase 2 | |
Completed |
NCT00986895 -
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
|
Phase 1 | |
Completed |
NCT00287235 -
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
|
N/A | |
Recruiting |
NCT05539027 -
Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy
|
Phase 4 | |
Recruiting |
NCT04096014 -
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
|
N/A | |
Completed |
NCT05526404 -
Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration
|
N/A | |
Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
Enrolling by invitation |
NCT06367127 -
Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
|
||
Active, not recruiting |
NCT05425316 -
Speech in Hepatic Encephalopathy (HE)
|
||
Recruiting |
NCT04415294 -
Flicker App for Minimal Hepatic Encephalopathy
|
||
Not yet recruiting |
NCT06072521 -
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
|
Phase 2 | |
Withdrawn |
NCT02086825 -
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
|
Phase 3 | |
Completed |
NCT02636647 -
Fecal Transplant in Recurrent Hepatic Encephalopathy
|
Phase 1 | |
Completed |
NCT01446523 -
S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
|
N/A | |
Completed |
NCT01218568 -
Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial
|
N/A |